Effectiveness of anticancer activity of DMU-214 (3'-hydroxy-3,4,5,4'-tetrametoxystilbene) in personalized treatment for ovarian cancer
2016/23/D/NZ7/03954
Keywords
Descriptors
- NZ5_7: Leczenie chorób człowieka
- NZ7_14: Farmacja, farmakoterapia, farmakologia
- NZ7_15: Toksykologia
Panel
NZ7 – Diagnostic tools, therapies and public health: public health, epidemiology, environmental health risks and occupational medicine, medical ethics, drug discovery and therapies, pharmacology
Host institution
Uniwersytet Medyczny im. Karola Marcinkowskiego w Poznaniu, Wydział Farmaceutyczny
Voivodeship: wielkopolskie
Principal investigator (from the host institution)
dr hab. Hanna Helena Piotrowska-Kempisty
Number of co-investigators in the project: 7
Call
SONATA 12 – announced on 2016-09-15
- Amount awarded
- 990 889 PLN
- Project start date
- 2017-09-20
- Project end date
- 2023-09-19
- Project duration
- 72 months (the same as in the proposal)
- Project status
- Project settled
Project description
Download the project description in a pdf file
Note — project descriptions were prepared by the authors of the applications themselves and placed in the system in an unchanged form.
Information in the final report
Publication in academic press/journals (1)
-
Enhanced biological activity of liposomal methylated resveratrol analog 3′-hydroxy-3,4,5,4′-tetramethoxystilbene (DMU-214) in 3D patient-derived ovarian cancer model
- Authors:
- Andrzej Nowicki, Dariusz Wawrzyniak, Mikołaj Czajkowski, Małgorzata Józkowiak, Michał Pawlak, Marcin Wierzchowski, Katarzyna Rolle, Paulina Skupin-Mrugalska, Hanna Piotrowska-Kempisty
- Academic press:
- Drug Delivery (year: 2022, volume: 29, pages: 2459-2468), Publisher: taylor & francis
- Status:
- Published
- DOI:
- 10.1080/10717544.2022.2103210 – link to the publication